Meeting Banner
Abstract #4338

Metabolic Modulation for Enhanced Therapeutic Response

Kavindra Nath1, Stepan Orlovskiy1, Jeffrey Roman1, David S. Nelson1, Dennis B. Leeper2, Paul D. Smith3, Mary E. Putt4, Vivek Narayan5, and Jerry D. Glickson1

1Radiology, University of Pennsylvania, Philadelphia, PA, United States, 2Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States, 3Cancer Biosciences, Cancer Research UK Cambridge Institute, AstraZeneca, Cambridge, United Kingdom, 4Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, United States, 5Medicine, University of Pennsylvania, Philadelphia, PA, United States

SYNOPSIS: Metastatic prostate cancer is treated with androgen deprivation therapy (ADT), which involves the maximal suppression of circulating testosterone. Although initial responses are generally favorable, most cases progress to metastatic castration resistant prostate cancer (mCRPC), which is refractory to standard ADT. Our goal is to develop a treatment strategy to improve response of mCRPC by combining a clinically utilized metabolic modulator, AZD3965, with docetaxel. AZD3965 effects were measured in vivo by 31P and 1H MRS in PC3 prostate cancer xenografts. In vitro results suggest that AZD3965 enhances the growth inhibitory effect of docetaxel similarly both in PC3 and LNCaP cells although PC3 expresses both MCT1 & 4 and LNCaP only expresses MCT1.

This abstract and the presentation materials are available to members only; a login is required.

Join Here